This company seems to have been delisted
Reason: Filed for chapter 11 bankruptcy
Last recorded trade on: March 12, 2024
Source: https://www.fiercebiotech.com/biotech/athersys-files-bankruptcy-sells-assets-healios-wake-roke-cell-therapys-struggles
Reason: Filed for chapter 11 bankruptcy
Last recorded trade on: March 12, 2024
Source: https://www.fiercebiotech.com/biotech/athersys-files-bankruptcy-sells-assets-healios-wake-roke-cell-therapys-struggles
Athersys
ATHX
₹1.16
Share price
-33.50%
Change (1 day)
-98.87%
Change (1 year)
Categories
P/S ratio for Athersys (ATHX)
P/S ratio on March 12, 2024 (TTM) : 10.4
According to Athersys's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -0.0229. At the end of 2023 the company had a P/S ratio of 144.
P/S ratio history for Athersys from 2008 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 144 | 5214.19% |
| 2022 | 2.72 | -92.95% |
| 2021 | 38.5 | -84.4% |
| 2020 | 247 | 592.84% |
| 2019 | 35.6 | 306.98% |
| 2018 | 8.75 | -88.4% |
| 2017 | 75.5 | 833.48% |
| 2016 | 8.08 | -3.46% |
| 2015 | 8.37 | -98.05% |
| 2014 | 429 | 83.42% |
| 2013 | 234 | 2528.81% |
| 2012 | 8.90 | 126.49% |
| 2011 | 3.93 | -24.85% |
| 2010 | 5.23 | -85.55% |
| 2009 | 36.2 | 1219.72% |
| 2008 | 2.74 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 | 4.61 | -55.72% | 🇺🇸 USA |
 | 1.95 | -81.28% | 🇺🇸 USA |
 | 2.14 | -79.49% | 🇺🇸 USA |
 | 3.12 | -70.01% | 🇺🇸 USA |
 | 4.11 | -60.55% | 🇺🇸 USA |
 | 8.26 | -20.67% | 🇺🇸 USA |
 | N/A | N/A | 🇺🇸 USA |
 | 3.10 | -70.28% | 🇺🇸 USA |
 | 2.62 | -74.84% | 🇫🇷 France |